Trial Profile
Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and Safety
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Repaglinide/metformin (Primary) ; Rosiglitazone/metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 01 Oct 2009 Analysis comparing only twice-daily repaglinide/metformin with twice-daily rosiglitazone/metformin published in Diabetes, Obesity and Metabolism.
- 16 Jun 2009 Actual patient number (560) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.